Novartis, BMS reportedly halt trials; first serious blow to burgeoning field
— Novartis, BMS reportedly halt trials; first serious blow to burgeoning field
by John Gever, Contributing Writer, MedPage Today
September 1, 2026
• 3 min read
Two Big Pharma companies have reportedly paused their ongoing trials of chimeric antigen receptor (CAR) T-cell therapies in lupus and other autoimmune inflammatory diseases after some participants suffered severe adverse events, including three deaths.
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could…
The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient”…
Three patient deaths in Novartis' autoimmune CAR-T trials raise questions about risks of the therapy in non-fatal diseases.
Novartis paused 8 trials of its rap-cel therapy after patients died from a severe immune reaction; Bristol Myers followed as a…
Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of three patients who received Novartis’…
